Fitness Industry Embraces GLP-1 Integration Trend
The fitness industry is seeing three major shifts in 2026: rising participation globally, integration of GLP-1 medications (diabetes/weight loss drugs) into wellness programs, and rapid expansion of health & fitness associations worldwide. Studios and trainers are adapting routines to support members using these medications, emphasizing holistic health rather than just weight loss. This indicates a more personalized and medically integrated future for fitness.
The market for GLP-1 medications like Ozempic and Wegovy is projected to be worth around $100 billion by 2030, a disruptive force that is prompting fitness brands to adapt rather than compete. This has led to strategic shifts from major players, including traditional diet companies like WeightWatchers and Noom, who are now incorporating these drugs into their programs. One of the primary drivers for this integration is the significant muscle loss that can accompany rapid weight loss on these drugs, with some studies suggesting that up to 40% of weight lost is lean mass. To counteract this, fitness programs for GLP-1 users are heavily emphasizing strength and resistance training to preserve metabolically active muscle tissue. Luxury gym chain Equinox was among the first to formalize this with its "GLP-1 Protocol," a specialized training program for members on these medications, which has been rolled out to 80 clubs. Similarly, Life Time is piloting "in-house" GLP-1 services and launched a medical wellness concept called MIORA, while Xponential Fitness acquired the weight loss clinic Lindora. Digital fitness platforms are also entering the space, with brands like FitOn and obé Fitness partnering with weight loss companies Noom and Found, respectively. These collaborations have resulted in progressive strength training programs specifically designed for individuals on GLP-1 medications. Personal trainers are adapting their methods for clients on these drugs, focusing on building muscle and creating sustainable habits. They must also consider potential side effects like fatigue, nausea, and reduced appetite, which can impact workout intensity and the client's ability to consume enough protein for muscle recovery. The trend is creating a new potential market for gyms: individuals who previously avoided fitness centers due to obesity-related issues like physical pain or psychological discomfort. An investment banking firm predicts that the rise of GLP-1s could increase the total addressable market for fitness clubs by $6.8 billion in the U.S. alone.
